{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:26:06Z","timestamp":1754483166464,"version":"3.33.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-025-01505-y","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:48:10Z","timestamp":1737647290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial"],"prefix":"10.1007","author":[{"given":"Hiroyasu","family":"Kaneda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruko","family":"Daga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"1505_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M (2019) Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 20:625\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(19)30035-X","journal-title":"Lancet Oncol"},{"key":"1505_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2023.02.023","volume":"185","author":"R Saito","year":"2023","unstructured":"Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, Oizumi S, Takahashi K, Kagamu H, Tsubata Y, Seike M, Kikuchi T, Okamoto I, Satoshi M, Asahina H, Tanaka K, Sugio K, Kobayashi K (2023) Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: the OPAL Study. Eur J Cancer 185:83\u201393. https:\/\/doi.org\/10.1016\/j.ejca.2023.02.023","journal-title":"Eur J Cancer"},{"key":"1505_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","volume":"45","author":"S Peters","year":"2016","unstructured":"Peters S, Bexelius C, Munk V, Leighl N (2016) The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev 45:139\u2013162. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.009","journal-title":"Cancer Treat Rev"},{"key":"1505_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11523-022-00941-7","volume":"18","author":"S Popat","year":"2023","unstructured":"Popat S, Ahn MJ, Ekman S, Leighl NB, Ramalingam SS, Reungwetwattana T, Siva S, Tsuboi M, Wu YL, Yang JC (2023) Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies. Target Oncol 18:9\u201324. https:\/\/doi.org\/10.1007\/s11523-022-00941-7","journal-title":"Target Oncol"},{"key":"1505_CR5","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.21037\/tlcr-20-459","volume":"9","author":"J Schoenmaekers","year":"2020","unstructured":"Schoenmaekers J, Paats MS, Dingemans AC, Hendriks LEL (2020) Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: How to treat and when? Transl Lung Cancer Res 9:2599\u20132617. https:\/\/doi.org\/10.21037\/tlcr-20-459","journal-title":"Transl Lung Cancer Res"},{"key":"1505_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS (2018) for the FLAURA Investigators: osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"1505_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40:492\u2013516. https:\/\/doi.org\/10.1200\/JCO.21.02314","journal-title":"J Clin Oncol"},{"key":"1505_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","volume":"33","author":"A Passaro","year":"2022","unstructured":"Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, J\u00e4nne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S (2022) ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol 33:466\u2013487. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.003","journal-title":"Ann Oncol"},{"key":"1505_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M (2019) RELAY Study Investigators: Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:1655\u20131669. https:\/\/doi.org\/10.1016\/S1470-2045(19)30634-5","journal-title":"Lancet Oncol"},{"key":"1505_CR10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3389\/fonc.2020.00904","volume":"10","author":"F Chen","year":"2020","unstructured":"Chen F, Chen N, Yu Y, Cui J (2020) Efficacy and safety of epidermal growth factor receptor (EGFR) inhibitors plus antiangiogenic agents as first-line treatments for patients with advanced EGFR-mutated non-small cell lung cancer: a meta-analysis. Front Oncol 10:904. https:\/\/doi.org\/10.3389\/fonc.2020.00904","journal-title":"Front Oncol"},{"key":"1505_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2019.08.021","volume":"121","author":"T Jiang","year":"2019","unstructured":"Jiang T, Zhang Y, Li X, Zhao C, Chen X, Su C, Ren S, Yang N, Zhou C (2019) EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases. Eur J Cancer 121:98\u2013108. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.021","journal-title":"Eur J Cancer"},{"key":"1505_CR12","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1007\/s10637-021-01147-w","volume":"39","author":"H Kaneda","year":"2021","unstructured":"Kaneda H, Sawa K, Daga H, Okada A, Nakatani Y, Atagi S, Okishio K, Tani Y, Matsumoto Y, Ogawa K, Nakahama K, Izumi M, Mitsuoka S, Kawaguchi T (2021) Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases. Invest New Drugs 39:1598\u20131603. https:\/\/doi.org\/10.1007\/s10637-021-01147-w","journal-title":"Invest New Drugs"},{"key":"1505_CR13","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.21037\/tlcr-22-736","volume":"12","author":"K Nishio","year":"2023","unstructured":"Nishio K, Sakai K, Nishio M, Seto T, Visseren-Grul C, Carlsen M, Matsui T, Enatsu S, Nakagawa K (2023) Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study). Transl Lung Cancer Res 12:1702\u20131716. https:\/\/doi.org\/10.21037\/tlcr-22-736","journal-title":"Transl Lung Cancer Res"},{"key":"1505_CR14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41598-020-57624-4","volume":"10","author":"H Ishii","year":"2020","unstructured":"Ishii H, Azuma K, Sakai K, Naito Y, Matsuo N, Tokito T, Yamada K, Hoshino T, Nishio K (2020) Determination of somatic mutations and tumor mutation burden in plasma by CAPP-Seq during afatinib treatment in NSCLC patients resistance to osimertinib. Sci Rep 10:691. https:\/\/doi.org\/10.1038\/s41598-020-57624-4","journal-title":"Sci Rep"},{"key":"1505_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O\u2019Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur DG (2016) Exome aggregation consortium: analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285\u2013291. https:\/\/doi.org\/10.1038\/nature19057","journal-title":"Nature"},{"key":"1505_CR16","doi-asserted-by":"publisher","first-page":"30850","DOI":"10.18632\/oncotarget.5068","volume":"6","author":"H Ishii","year":"2015","unstructured":"Ishii H, Azuma K, Sakai K, Kawahara A, Yamada K, Tokito T, Okamoto I, Nishio K, Hoshino T (2015) Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: correlation with paired tumor samples. Oncotarget 6:30850\u201330858. https:\/\/doi.org\/10.18632\/oncotarget.5068","journal-title":"Oncotarget"},{"key":"1505_CR17","doi-asserted-by":"publisher","first-page":"S1313","DOI":"10.1016\/j.annonc.2023.10.072","volume":"34","author":"X Le","year":"2023","unstructured":"Le X, Patel J, Shum E, Sanborn RE, Baik CS, Shu CA, Kim C, Fidler MD, Hall R, Hanna N, Mohindra N, Sabari JK, Heeke S, Hernandez M, Gray JE, Heymach JV, Saltos A (2023) LBA71 A multi centre open label randomized phase ii study of osimertinib with and without ramucirumab in TKI na\u00efve EGFR mutant metastatic NSCLC (RAMOSE trial). Ann Oncol 34:S1313\u2013S1314. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.072","journal-title":"Ann Oncol"},{"key":"1505_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.annonc.2023.10.071","volume":"34","author":"T Misumi","year":"2023","unstructured":"Misumi T, Tamiya M, Yoh K, Furuya N, Ono A, Takiguchi Y, Koyama K, Ikeda S, Watanabe K, Tokito T, Seki N, Imai H, Shukuya T, Shibata Y, Hosokawa S, Kozuki T, Okamoto H (2023) LBA70 OSIRAM 1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non small cell lung cancer (TORG1833). Ann Oncol 34:1313. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.071","journal-title":"Ann Oncol"},{"key":"1505_CR19","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/ng.3990","volume":"49","author":"CM Blakely","year":"2017","unstructured":"Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG (2017) Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49:1693\u20131704. https:\/\/doi.org\/10.1038\/ng.3990","journal-title":"Nat Genet"},{"key":"1505_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis F, Heymach JV (2019) Co-occurring genomic alterations in\u00a0non-small-cell lung cancer biology and therapy. Nat Rev Cancer 19:495\u2013509. https:\/\/doi.org\/10.1038\/s41568-019-0179-8","journal-title":"Nat Rev Cancer"},{"key":"1505_CR21","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","volume":"7","author":"EJ Jordan","year":"2017","unstructured":"Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ (2017) Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 7:596\u2013609. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1337","journal-title":"Cancer Discov"},{"key":"1505_CR22","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","volume":"23","author":"M Canale","year":"2017","unstructured":"Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, Chiari R, Bennati C, Calistri D, Ludovini V, Crin\u00f2 L, Amadori D, Ulivi P (2017) Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res 23:2195\u20132202. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0966","journal-title":"Clin Cancer Res"},{"key":"1505_CR23","doi-asserted-by":"publisher","unstructured":"Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S, Bagley S, Gabriel P, Evans TL, Bauml JM, Ciunci C, Alley E, Morrissette JJD, Cohen RB, Carpenter EL, Langer CJ (2018) Influence of TP53 mutation on survival in patients with advanced EGFR-mutant non-small-cell lung cancer. JCO Precis Oncol 2. https:\/\/doi.org\/10.1200\/PO.18.00107","DOI":"10.1200\/PO.18.00107"},{"key":"1505_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","volume":"20","author":"K Qin","year":"2020","unstructured":"Qin K, Hou H, Liang Y, Zhang X (2020) Prognostic value of TP53 concurrent mutations for EGFR-TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. BMC Cancer 20:328. https:\/\/doi.org\/10.1186\/s12885-020-06805-5","journal-title":"BMC Cancer"},{"key":"1505_CR25","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1158\/2159-8290.CD-20-1385","volume":"11","author":"G Foggetti","year":"2021","unstructured":"Foggetti G, Li C, Cai H, Hellyer JA, Lin WY, Ayeni D, Hastings K, Choi J, Wurtz A, Andrejka L, Maghini DG, Rashleigh N, Levy S, Homer R, Gettinger SN, Diehn M, Wakelee HA, Petrov DA, Winslow MM, Politi K (2021) Genetic determinants of EGFR-driven lung cancer growth and therapeutic response in vivo. Cancer Discov 11:1736\u20131753. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1385","journal-title":"Cancer Discov"},{"key":"1505_CR26","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","volume":"17","author":"NI Vokes","year":"2022","unstructured":"Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, J\u00e4nne PA (2022) Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma. J Thorac Oncol 17:779\u2013792. https:\/\/doi.org\/10.1016\/j.jtho.2022.02.011","journal-title":"J Thorac Oncol"},{"key":"1505_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00432-018-02828-5","volume":"145","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Ma Y, Li Y, Shen X, Yu Y, Pan Y, Zhang Y, Zheng D, Zhao Y, Ye T, Li B, Hu H, Sun Y, Zhang Y, Xiang J, Chen H (2019) Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations. J Cancer Res Clin Oncol 145:747\u2013757. https:\/\/doi.org\/10.1007\/s00432-018-02828-5","journal-title":"J Cancer Res Clin Oncol"},{"key":"1505_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jtho.2023.10.001","volume":"19","author":"P Stockhammer","year":"2024","unstructured":"Stockhammer P, Grant M, Wurtz A, Foggetti G, Exp\u00f3sito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg SB (2024) Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer. J Thorac Oncol 19:240\u2013251. https:\/\/doi.org\/10.1016\/j.jtho.2023.10.001","journal-title":"J Thorac Oncol"},{"key":"1505_CR29","doi-asserted-by":"publisher","unstructured":"Canale M, Petracci E, Delmonte A, Bronte G, Chiadini E, Ludovini V, Dubini A, Papi M, Baglivo S, De Luigi N, Verlicchi A, Chiari R, Landi L, Metro G, Burgio MA, Crin\u00f2 L, Ulivi P (2020) Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs. J Clin Med 9. https:\/\/doi.org\/10.3390\/jcm9041047","DOI":"10.3390\/jcm9041047"},{"key":"1505_CR30","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1111\/1759-7714.13154","volume":"10","author":"PN Ding","year":"2019","unstructured":"Ding PN, Becker T, Bray V, Chua W, Ma Y, Xu B, Lynch D, de Souza P, Roberts T (2019) Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib. Thorac Cancer 10:1879\u20131884. https:\/\/doi.org\/10.1111\/1759-7714.13154","journal-title":"Thorac Cancer"},{"key":"1505_CR31","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1158\/1078-0432.CCR-21-0273","volume":"27","author":"K Nakagawa","year":"2021","unstructured":"Nakagawa K, Nadal E, Garon EB, Nishio M, Seto T, Yamamoto N, Park K, Shih JY, Paz-Ares L, Frimodt-Moller B, Zimmermann AH, Wijayawardana S, Visseren-Grul C, Reck M (2021) RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung cancer. Clin Cancer Res 27:5258\u20135271. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0273","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1505_CR32","doi-asserted-by":"publisher","first-page":"e586","DOI":"10.1002\/mco2.586","volume":"5","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Xue J, Yang Y, Fang W, Huang Y, Zhao S, Luo F, Cao J, Zeng K, Ma W, Zhan J, Lu F, Zhang L, Zhao H (2024) Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors. MedComm 5(6):e586. https:\/\/doi.org\/10.1002\/mco2.586","journal-title":"MedComm"},{"key":"1505_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen B, Fong C, Luthra A, Smith SA, DiNatale RG, Nandakumar S, Walch H, Chatila WK, Madupuri R, Kundra R, Bielski CM, Mastrogiacomo B, Donoghue MTA, Boire A, Chandarlapaty S, Ganesh K, Harding JJ, Iacobuzio-Donahue CA, Razavi P, Reznik E, Rudin CM, Zamarin D, Abida W, Abou-Alfa GK, Aghajanian C, Cercek A, Chi P, Feldman D, Ho AL, Iyer G, Janjigian YY, Morris M, Motzer RJ, O\u2019Reilly EM, Postow MA, Raj NP, Riely GJ, Robson ME, Rosenberg JE, Safonov A, Shoushtari AN, Tap W, Teo MY, Varghese AM, Voss M, Yaeger R, Zauderer MG, Abu-Rustum N, Garcia-Aguilar J, Bochner B, Hakimi A, Jarnagin WR, Jones DR, Molena D, Morris L, Rios-Doria E, Russo P, Singer S, Strong VE, Chakravarty D, Ellenson LH, Gopalan A, Reis-Filho JS, Weigelt B, Ladanyi M, Gonen M, Shah SP, Massague J, Gao J, Zehir A, Berger MF, Solit DB, Bakhoum SF, Sanchez-Vega F, Schultz N (2022) Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185:563-575.e511. https:\/\/doi.org\/10.1016\/j.cell.2022.01.003","journal-title":"Cell"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01505-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01505-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01505-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:48:13Z","timestamp":1737647293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01505-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":33,"alternative-id":["1505"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01505-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Hiroyasu Kaneda reports financial support and equipment, drugs, or supplies were provided by Elli Lilly. Hiroyasu Kaneda reports a relationship with AstraZeneca that includes: speaking and lecture fees. Hiroyasu Kaneda reports a relationship with Chugai Pharmaceutical that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Haruko Daga reports a relationship with Astrazeneca that includes: speaking and lecture fees. Haruko Daga reports a relationship with Chugai Pharmaceutical Co Ltd that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Kazuko Sakai reports a relationship with Life Technologies Japan Ltd.  that includes: speaking and lecture fees. Kazuko Sakai reports a relationship with Takeda Pharmaceutical Co., Ltd. that includes: speaking and lecture fees. Kazuko Sakai reports a relationship with Qiagen, Inc. that includes: speaking and lecture fees. Kazuko Sakai reports a relationship with Nippon Kayaku Co.,Ltd. that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Kenji Sawa reports a relationship with Taiho Pharmaceutical Co Ltd that includes: speaking and lecture fees. Kenji Sawa reports a relationship with Chugai Pharmaceutical Co Ltd that includes: speaking and lecture fees. Kenji Sawa reports a relationship with AstraZeneca that includes: speaking and lecture fees. Kenji Sawa reports a relationship with MSD KK that includes: speaking and lecture fees. Kenji Sawa reports a relationship with Ono Pharmaceutical Co Ltd that includes: speaking and lecture fees. Kenji Sawa reports a relationship with Nippon Kayaku Co Ltd that includes: speaking and lecture fees. Kenji Sawa reports a relationship with Kyowa Kirin Co Ltd that includes: speaking and lecture fees. Kenji Sawa reports a relationship with Eli Lilly Japan KK that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Kazuto Nishio reports a relationship with Nichirei Biosciences Inc that includes: funding grants and speaking and lecture fees. Kazuto Nishio reports a relationship with West Japan Oncology Group that includes: funding grants. Kazuto Nishio reports a relationship with Eli Lilly Japan KK that includes: funding grants and speaking and lecture fees. Kazuto Nishio reports a relationship with Hitachi Ltd that includes: funding grants. Kazuto Nishio reports a relationship with Nippon Boehringer Ingelheim Co Ltd that includes: funding grants and speaking and lecture fees. Kazuto Nishio reports a relationship with Sysmex Corp that includes: funding grants. Kazuto Nishio reports a relationship with Otsuka pharmaceutical that includes: funding grants and speaking and lecture fees. Kazuto Nishio reports a relationship with Thoracic Oncology Research Group that includes: funding grants. Kazuto Nishio reports a relationship with University Public Corporation Osaka that includes: funding grants. Kazuto Nishio reports a relationship with Chugai Pharmaceutical Co Ltd that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with AstraZeneca that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Amgen Inc that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Yakult Honsha Co Ltd that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Guardant Health Inc that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with SymBio Pharmaceuticals Limited that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Takeda Pharmaceutical Company Limited that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Novartis Pharmaceuticals Corporation that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Pfizer Inc that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with FUJIREBIO that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Bristol-Myers Squibb that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Merck Biopharma Deutschland that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with MSD that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Daiichi Sankyo Inc that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Ono Pharmaceutical Co Ltd that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Invitae Japan that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Maruho Co Ltd that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Tomoya Kawaguchi reports non-financial support from Eli Lilly co., during the conduct of the study; grants and personal fees from Chugai Pharma, grants and personal fees from Eli Lilly, personal fees from Astra Zeneca, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Bristol-Myers Squibb Japan, personal fees from MSD Oncology, personal fees from Pfizer, personal fees from Novartis, grants from Daiichi Sankyo, personal fees from Astellas Pharma, outside the submitted work.The remaining authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}